495 related articles for article (PubMed ID: 11477592)
1. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
3. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
4. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
5. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
6. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
8. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
9. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
11. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
13. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
14. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
Okegawa T; Noda H; Nutahara K; Higashihara E
Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
[TBL] [Abstract][Full Text] [Related]
16. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
17. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
19. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
Björk T; Lilja H; Christensson A
BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]